HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma

PURPOSE: The clinical use of MEK inhibitors in uveal melanoma is limited by the rapid acquisition of resistance. The current study has used multi-omics approaches and drug screens to identify the pan-HDAC inhibitor panobinostat as an effective strategy to limit MEK inhibitor resistance. EXPERIMENTAL...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Faião-Flores, Fernanda, Emmons, Michael F., Durante, Michael A., Kinose, Fumi, Saha, Biswarup, Fang, Bin, Koomen, John M., Chellappan, Srikumar, Maria-Engler, Silvya Stuchi, Rix, Uwe, Licht, Jonathan D., Harbour, J. William, Smalley, Keiran S.M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6744978/
https://ncbi.nlm.nih.gov/pubmed/31227503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3382
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi